Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Profound Medical stock

PRN.TO
CA74319B5027

Price

7.88
Today +/-
+0.06
Today %
+0.78 %
P

Profound Medical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Profound Medical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Profound Medical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Profound Medical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Profound Medical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Profound Medical Stock Price History

DateProfound Medical Price
11/18/20247.88 undefined
11/15/20247.82 undefined
11/14/20248.04 undefined
11/13/20248.03 undefined
11/12/20248.12 undefined
11/11/20248.20 undefined
11/8/20248.61 undefined
11/7/20248.91 undefined
11/6/20248.03 undefined
11/5/20247.91 undefined
11/4/20248.21 undefined
11/1/20247.38 undefined
10/31/20247.29 undefined
10/30/20247.47 undefined
10/29/20247.40 undefined
10/28/20247.51 undefined
10/25/20247.26 undefined
10/24/20247.20 undefined
10/23/20247.23 undefined
10/22/20247.45 undefined
10/21/20247.46 undefined

Profound Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Profound Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Profound Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Profound Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Profound Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Profound Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Profound Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Profound Medical’s growth potential.

Profound Medical Revenue, EBIT and net profit per share

DateProfound Medical RevenueProfound Medical EBITProfound Medical Net Income
2029e136.6 M undefined0 undefined78.59 M undefined
2028e106.72 M undefined-10.22 M undefined-2.49 M undefined
2027e99.65 M undefined40.9 M undefined38.64 M undefined
2026e52.96 M undefined-15.2 M undefined-11.89 M undefined
2025e30.56 M undefined-25.41 M undefined-22.73 M undefined
2024e11.24 M undefined-30.79 M undefined-27.84 M undefined
20237.2 M undefined-28.62 M undefined-28.57 M undefined
20226.68 M undefined-29.6 M undefined-28.67 M undefined
20216.87 M undefined-30.29 M undefined-30.7 M undefined
20207.3 M undefined-18.86 M undefined-21.62 M undefined
20194.17 M undefined-14.9 M undefined-15.22 M undefined
20182.01 M undefined-15.58 M undefined-16.02 M undefined
20173.78 M undefined-13.58 M undefined-14.51 M undefined
20160 undefined-11.81 M undefined-12.32 M undefined
20150 undefined-8.78 M undefined-12.81 M undefined
20140 undefined-3.93 M undefined-7.43 M undefined

Profound Medical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000324766711305299106136
-----33.33100.0075.00-14.29-16.6757.14172.7373.3390.387.0728.30
---33.33200.0050.0042.8633.3350.0057.1436.3613.337.694.043.772.94
0001023234000000
-7-12-12-14-16-15-21-30-28-28-27-22-1138-278
-71.43-16.6714.29-6.2540.0042.86-6.67--3.57-18.52-50.00-445.45-105.26-4,000.00
0.222.374.156.1410.0411.117.2920.4620.8321.18000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Profound Medical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Profound Medical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
0.3514.8315.518.8322.514.883.9167.1546.5226.21
0003.381.971.996.450.975.846.75
0000.190.351.320.990.440.510.53
000.311.142.663.675.337.417.946.99
0.530.10.520.460.321.031.071.151.221.41
0.8814.9316.341427.8122.8197.7477.1362.0241.9
0.150.170.711.370.892.222.281.91.721.53
0000000000
00000003.6200
0.030.020.24.092.942.411.91.440.680.49
0002.712.52.632.682.6900
0000000000
0.180.190.918.176.337.256.869.652.42.01
1.0615.1217.2522.1734.1430.06104.686.7864.4243.91
                   
0.0348.4762.0178.2188.68100.3211.53219.58205.83217.39
0.661.452.234.8512.2915.0811.2516.9918.719.69
-33.35-39.83-53.2-71.77-81.42-108.37-129.99-160.69-189.36-217.93
000.01-0.05-0.027.374.574.7516.8412.03
0000000000
-32.6610.0911.0511.2419.5314.3797.3580.625231.18
1.390.711.324.042.873.033.383.182.033.28
0000000000
30.4900.220.751.931.041.120.731.390.72
603000000000
0.110.212.143.740.984.160.310.250.762.36
32.60.913.688.535.788.224.814.164.196.37
1.684.022.80.357.786.811.361.137.475.58
00000000059
0.630.290.112.041.050.651.080.880.760.73
2.34.312.912.48.837.472.4428.236.37
34.95.226.5910.9214.6115.697.256.1612.4212.73
2.2515.3117.6422.1734.1430.06104.686.7764.4243.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Profound Medical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Profound Medical's financial health and stability.

Assets

Profound Medical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Profound Medical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Profound Medical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Profound Medical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-7-12-12-14-16-15-21-30-28-28
00001,0001,0001,0001,0001,0001,000
0000000000
1,000000-1,000-3,000-5,000-1,000-3,0000
3712125744
0000000000
0000000000
-2-5-10-11-14-15-20-22-25-22
0000000000
0-760000000
0-670000000
0000000000
030-25-1-900-1
118137268103602
22012429687571
0-200-20-6070
0000000000
077-715-769-16-20-20
-2.67-5.5-11.77-12.36-14.12-15.24-20.92-22.95-25.8-22.3
0000000000

Profound Medical stock margins

The Profound Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Profound Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Profound Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Profound Medical's sales revenue. A higher gross margin percentage indicates that the Profound Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Profound Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Profound Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Profound Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Profound Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Profound Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Profound Medical Margin History

Profound Medical Gross marginProfound Medical Profit marginProfound Medical EBIT marginProfound Medical Profit margin
2029e60.87 %0 %57.54 %
2028e60.87 %-9.58 %-2.33 %
2027e60.87 %41.04 %38.78 %
2026e60.87 %-28.7 %-22.46 %
2025e60.87 %-83.12 %-74.37 %
2024e60.87 %-273.97 %-247.69 %
202360.87 %-397.5 %-396.85 %
202245.22 %-443.08 %-429.11 %
202142.95 %-440.72 %-446.66 %
202047.56 %-258.26 %-296.03 %
201957.26 %-357.07 %-364.69 %
201831.65 %-775.85 %-797.88 %
201738.18 %-359.4 %-383.77 %
201660.87 %0 %0 %
201560.87 %0 %0 %
201460.87 %0 %0 %

Profound Medical Stock Sales Revenue, EBIT, Earnings per Share

The Profound Medical earnings per share therefore indicates how much revenue Profound Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Profound Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Profound Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Profound Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Profound Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Profound Medical Revenue, EBIT and net profit per share

DateProfound Medical Sales per ShareProfound Medical EBIT per shareProfound Medical Earnings per Share
2029e5.54 undefined0 undefined3.19 undefined
2028e4.33 undefined0 undefined-0.1 undefined
2027e4.04 undefined0 undefined1.57 undefined
2026e2.15 undefined0 undefined-0.48 undefined
2025e1.24 undefined0 undefined-0.92 undefined
2024e0.46 undefined0 undefined-1.13 undefined
20230.34 undefined-1.35 undefined-1.35 undefined
20220.32 undefined-1.42 undefined-1.38 undefined
20210.34 undefined-1.48 undefined-1.5 undefined
20200.42 undefined-1.09 undefined-1.25 undefined
20190.38 undefined-1.34 undefined-1.37 undefined
20180.2 undefined-1.55 undefined-1.6 undefined
20170.62 undefined-2.21 undefined-2.36 undefined
20160 undefined-2.84 undefined-2.97 undefined
20150 undefined-3.71 undefined-5.41 undefined
20140 undefined-18.13 undefined-34.28 undefined

Profound Medical business model

Profound Medical is a Canadian medical technology company specializing in the development and marketing of innovative therapy devices for the treatment of prostate cancer and other diseases. Profound Medical is one of the most popular companies on Eulerpool.com.

Profound Medical SWOT Analysis

Strengths

Profound Medical Corp has a strong track record of technological innovation in the field of medical devices, particularly in the area of non-invasive surgical technologies. This has enabled the company to develop groundbreaking products that have revolutionized patient care.

The company possesses an extensive intellectual property portfolio, including patents, trademarks, and trade secrets, which provides a significant competitive advantage in the market. This helps protect their innovative technologies from being replicated by competitors.

Profound Medical Corp is led by a highly experienced management team with deep industry knowledge and expertise. Their collective leadership skills and strategic vision have played a crucial role in driving the company's growth and success.

Weaknesses

Despite their innovative products, Profound Medical Corp faces the challenge of limited market reach, primarily due to the niche nature of their target market. This may impact their revenue potential and hinder their ability to scale up rapidly.

Developing advanced medical technologies requires substantial investment in research and development. Profound Medical Corp may face challenges in consistently funding these activities, especially during economic downturns, which could impact their ability to stay at the forefront of innovation.

As a medical device company, Profound Medical Corp heavily relies on regulatory approvals from various authorities. Any delays or difficulties in obtaining necessary approvals can significantly impact their product launch timelines and overall market competitiveness.

Opportunities

The market for non-invasive surgical technologies is on the rise, driven by increasing patient preference for minimally invasive procedures and improvements in healthcare infrastructure. Profound Medical Corp can capitalize on this trend by expanding their product offerings and capturing a larger market share.

With their innovative products, Profound Medical Corp can enter emerging markets where there is a growing need for advanced medical technologies. These markets offer significant growth potential and can diversify the company's revenue streams.

Forming strategic partnerships and collaborations with healthcare organizations, research institutions, and key opinion leaders can provide Profound Medical Corp with access to expertise, resources, and a wider customer base. This can enhance their market presence and accelerate product development.

Threats

The medical device industry is highly competitive, with numerous established players and new entrants vying for market share. Profound Medical Corp faces the risk of intense competition, which may result in price pressure, reduced profit margins, and the need for continuous innovation.

Strict regulations and compliance requirements in the healthcare industry pose challenges to Profound Medical Corp. The company needs to ensure full compliance with regulatory standards and adapt quickly to any changes, as non-compliance can lead to penalties, reputational damage, and potential product recalls.

The medical device industry is characterized by rapid technological advancements. There is a risk that Profound Medical Corp's innovative products may become obsolete if they fail to keep up with emerging technologies. The company needs to invest in research and development to stay at the forefront of industry trends.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Profound Medical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Profound Medical historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Profound Medical shares outstanding

The number of shares was Profound Medical in 2023 — This indicates how many shares 21.183 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Profound Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Profound Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Profound Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Profound Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Profound Medical stock splits

In Profound Medical's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Profound Medical.

Profound Medical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.3 -0.38  (-28.64 %)2024 Q3
6/30/2024-0.29 -0.28  (5.05 %)2024 Q2
3/31/2024-0.28 -0.26  (6.41 %)2024 Q1
12/31/2023-0.32 -0.42  (-30.15 %)2023 Q4
9/30/2023-0.34 -0.26  (23.48 %)2023 Q3
6/30/2023-0.36 -0.35  (2.34 %)2023 Q2
3/31/2023-0.36 -0.32  (11.99 %)2023 Q1
12/31/2022-0.37 -0.46  (-23.09 %)2022 Q4
9/30/2022-0.37 -0.24  (35.19 %)2022 Q3
6/30/2022-0.4 -0.28  (29.52 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Profound Medical stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

29

👫 Social

40

🏛️ Governance

15

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Profound Medical shareholders

%
Name
Stocks
Change
Date
6.11683 % Gagnon Securities LLC1,508,521-20,5166/30/2024
6.10256 % Fidelity Investments Canada ULC1,505,000154,3656/30/2024
4.96103 % BDC Venture Capital1,223,4801,223,4807/31/2024
4.86086 % Letko, Brosseau & Associates Inc.1,198,77509/30/2024
4.48061 % Daseke Don R1,105,00003/7/2024
3.08354 % Raymond James Financial Services Advisors, Inc.760,45778,8959/30/2024
3.02989 % Gagnon Advisors, LLC747,22606/30/2024
2.94340 % Timelo Investment Management Inc.725,895-129,9516/30/2024
2.29423 % Royce Investment Partners565,7981,5006/30/2024
2.16259 % Rosalind Advisors, Inc.533,33306/30/2024
1
2
3
4
5
...
9

Profound Medical Executives and Management Board

Dr. Arun Menawat(68)
Profound Medical Chairman of the Board, Chief Executive Officer (since 2015)
Compensation 916,378
Ms. Abbey Goodman(40)
Profound Medical Chief Commercial Officer, US
Compensation 645,352
Mr. Rashed Dewan(55)
Profound Medical Chief Accounting Officer, Vice President - Finance
Compensation 541,976
Mr. Mathieu Burtnyk(41)
Profound Medical Senior Vice President - Product Leader
Compensation 537,703
Mr. Hartmut Warnken(50)
Profound Medical Chief Commercial Officer - OUS
Compensation 516,533
1
2
3

Most common questions regarding Profound Medical

What values and corporate philosophy does Profound Medical represent?

Profound Medical Corp is committed to transforming the lives of patients with minimally invasive, incision-free therapies for the treatment of prostate disease. Their corporate philosophy revolves around innovation, patient-centricity, and a dedication to advancing medical technologies. By leveraging their cutting-edge TULSA-PRO® system, Profound Medical Corp aims to provide precise and personalized treatments, reducing potential side effects while enhancing treatment outcomes. With a focus on research and development, they strive to continuously improve their therapeutic offerings and expand their reach globally. Profound Medical Corp's values encompass integrity, collaboration, and a commitment to revolutionizing healthcare through their transformative solutions.

In which countries and regions is Profound Medical primarily present?

Profound Medical Corp primarily operates in the United States, Canada, and Europe.

What significant milestones has the company Profound Medical achieved?

Profound Medical Corp, a leading medical device company, has achieved several significant milestones. Firstly, they received FDA approval for their revolutionary TULSA-PRO system, which offers non-invasive treatment for prostate cancer. This milestone has positioned Profound Medical Corp as a game-changer in the field of prostate cancer treatments. Additionally, the company successfully completed a clinical trial, showcasing the TULSA-PRO system's remarkable efficacy and safety profile. Furthermore, Profound Medical Corp expanded its market reach by establishing strategic partnerships with renowned cancer centers and leading healthcare providers. Through continuous innovation and collaboration, Profound Medical Corp has cemented its position as a trailblazer in the fight against prostate cancer.

What is the history and background of the company Profound Medical?

Profound Medical Corp is a prominent medical technology company that focuses on developing and commercializing innovative treatments for prostate cancer. Established in 2008, Profound Medical has made significant strides in the field of image-guided therapy. Their flagship product, TULSA-PRO, utilizes MRI and ultrasound technology to deliver precise and personalized thermal ablation treatments, effectively destroying targeted prostate tissue while minimizing damage to surrounding areas. This revolutionary approach provides patients with a non-invasive or minimally invasive option, reducing side effects and improving outcomes. Profound Medical Corp continues to advance the field of prostate cancer treatment, offering hope to patients worldwide.

Who are the main competitors of Profound Medical in the market?

The main competitors of Profound Medical Corp in the market include SonaCare Medical, Inc., EDAP TMS S.A., and Exact Imaging Inc.

In which industries is Profound Medical primarily active?

Profound Medical Corp is primarily active in the medical industry.

What is the business model of Profound Medical?

Profound Medical Corp is a medical technology company specializing in the development of real-time magnetic resonance imaging (MRI) guided ablation devices for the treatment of diseases such as prostate cancer. The company's business model revolves around the creation and commercialization of innovative solutions that enable precise and personalized ablation procedures. Profound's devices utilize thermal energy to heat and destroy targeted tissue while providing real-time feedback to clinicians for enhanced safety and efficacy. By leveraging cutting-edge MRI technology, Profound Medical Corp aims to optimize patient outcomes in the field of minimally invasive therapies, positioning itself as a leader in the evolving landscape of image-guided treatments.

What is the P/E ratio of Profound Medical 2024?

The Profound Medical P/E ratio is -6.

What is the P/S ratio of Profound Medical 2024?

The Profound Medical P/S ratio is 14.86.

What is the Quality Investing of Profound Medical?

The Quality Investing for Profound Medical is 3/10.

What is the revenue of Profound Medical 2024?

The expected Profound Medical revenue is 11.24 M USD.

How high is the profit of Profound Medical 2024?

The expected Profound Medical profit is -27.84 M USD.

What is the business model of Profound Medical

Profound Medical Corp is a leading company in the development of innovative medical technologies for the treatment of prostate cancer. The company's business model is based on the development and marketing of its advanced therapy systems for the treatment of localized prostate cancer. The divisions of Profound Medical Corp include research and development, marketing and distribution of medical devices. The company focuses on developing medical products that meet the patients' need for state-of-the-art, minimally invasive treatments. The devices of Profound Medical Corp are targeted towards the target group of urologists and radiation therapists. The main product of Profound Medical Corp is the TULSA-PRO® System, an innovative HIFU (High-Intensity Focused Ultrasound) system that enables the minimally invasive treatment of localized prostate cancer. The technology is based on an ultrasound device that destroys the diseased tissue in the prostate using sound waves without damaging the surrounding tissue. The minimally invasive procedure is performed on an outpatient basis and minimizes the risk of complications and side effects. The TULSA-PRO® System offers many advantages compared to other conventional treatment methods. For example, it is gentler and faster than radiation therapy or surgery and has a better success rate than the use of chemotherapy or hormonal therapies. In addition, the TULSA-PRO® System is approved by the FDA, the American Food and Drug Administration, and CE-marked. The company also provides comprehensive training and technical support for users of the TULSA-PRO® System. Therefore, consulting, device management, and continuous maintenance are further services offered by Profound Medical Corp. In the course of its business activities, the company strives for close cooperation with leading research institutions and specialists in the field of cancer treatment. The goal is to develop innovative technologies that improve the diagnosis and treatment of prostate cancer and increase the quality of life of affected patients. In conclusion, the business model of Profound Medical Corp is focused on the needs of patients and their doctors. With the development and marketing of innovative medical devices, the company offers advanced technology that enables minimally invasive treatment of prostate cancer. Through collaboration with leading research institutions, Profound Medical Corp further expands its expertise in the field of cancer treatment.

What is the Profound Medical dividend?

Profound Medical pays a dividend of 0 USD distributed over payouts per year.

How often does Profound Medical pay dividends?

The dividend cannot currently be calculated for Profound Medical or the company does not pay out a dividend.

What is the Profound Medical ISIN?

The ISIN of Profound Medical is CA74319B5027.

What is the Profound Medical ticker?

The ticker of Profound Medical is PRN.TO.

How much dividend does Profound Medical pay?

Over the past 12 months, Profound Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Profound Medical is expected to pay a dividend of 0 USD.

What is the dividend yield of Profound Medical?

The current dividend yield of Profound Medical is .

When does Profound Medical pay dividends?

Profound Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Profound Medical?

Profound Medical paid dividends every year for the past 0 years.

What is the dividend of Profound Medical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Profound Medical located?

Profound Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Profound Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Profound Medical from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Profound Medical pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Profound Medical in the year 2023?

In the year 2023, Profound Medical distributed 0 USD as dividends.

In which currency does Profound Medical pay out the dividend?

The dividends of Profound Medical are distributed in USD.

All fundamentals about Profound Medical

Our stock analysis for Profound Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Profound Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.